Copy number aberrations drive kinase rewiring, leading to genetic vulnerabilities in cancer

Area of Science:

• Oncology
• Genomics
• Proteomics
• Cancer Signaling

Background:

• Somatic DNA copy number variations (CNVs) are common in cancer and influence disease progression.
• The specific roles of CNVs in altering cell signaling pathways remain largely uncharacterized.

Purpose of the Study:

• To integrate genomic and proteomic data to identify CNVs that lead to aberrant signal transduction in cancer.
• To discover novel kinase-substrate relationships and causal genes driven by CNVs.
• To explore the potential of CNV status as a predictive biomarker for kinase inhibitor efficacy in cancer therapy.

Main Methods:

• Integration of genomic and proteomic data from 5,598 tumor samples.
• Network analysis to prioritize candidate genes.
• Experimental validation of predicted regulators, including Hippo signaling pathway components.
• Analysis of RNA interference (RNAi), CRISPR, and drug screening data.

Main Results:

• Identification of 303 significant CNV-associated aberrant signal transduction events.
• Replication of 43% of these associations in cancer cell lines, including 44 robust gene-phosphosite associations across multiple tumor types.
• Experimental validation of several predicted regulators of the Hippo signaling pathway.
• Evidence of kinase addiction in cancer cell lines and identification of effective kinase inhibitors.

Conclusions:

• CNVs significantly contribute to aberrant signaling in cancer.
• Gene copy number status can predict the differential impact of kinase inhibition.
• This approach offers a promising strategy for developing future anticancer therapies targeting kinase dependencies.